<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report" xml:lang="en">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">World J Surg Oncol</journal-id>
      <journal-id journal-id-type="iso-abbrev">World J Surg Oncol</journal-id>
      <journal-title-group>
        <journal-title>World Journal of Surgical Oncology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1477-7819</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">22747970</article-id>
      <article-id pub-id-type="pmc">3478189</article-id>
      <article-id pub-id-type="publisher-id">1477-7819-10-129</article-id>
      <article-id pub-id-type="doi">10.1186/1477-7819-10-129</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Possibility of sandwiched liver surgery with molecular targeting drugs, cetuximab and bevacizumab on colon cancer liver metastases: a case report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes" id="A1">
          <name>
            <surname>Toyama</surname>
            <given-names>Yoichi</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>yoichitoyama@jikei.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Ushigome</surname>
            <given-names>Takuro</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>gomeushi@qf7.so-net.ne.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Watanabe</surname>
            <given-names>Kazuhiro</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>k.watanabe@jikei.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Kitamura</surname>
            <given-names>Hiroaki</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>777333aaa@gmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A5">
          <name>
            <surname>Onda</surname>
            <given-names>Shinji</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>a.onda@jikei.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A6">
          <name>
            <surname>Saito</surname>
            <given-names>Ryota</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>ryota.s@jikei.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A7">
          <name>
            <surname>Yoshida</surname>
            <given-names>Seiya</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>yansei@jikei.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A8">
          <name>
            <surname>Kawahara</surname>
            <given-names>Hidejiro</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>kawahide@jikei.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A9">
          <name>
            <surname>Yanagisawa</surname>
            <given-names>Satoru</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>yanagisawa@jikei.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A10">
          <name>
            <surname>Yanaga</surname>
            <given-names>Katsuhiko</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>kyanaga@jikei.ac.jp</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Department of Surgery, The Jikei University Kashiwa Hospital, 163-1, Kashiwashita, Chiba Prefecture, Kashiwa City 277-8567, Japan</aff>
      <aff id="I2"><label>2</label>Department of Surgery, The Jikei University School of Medicine, 3-25-8, , Nishishinnbashi, Minato ku, Tokyo, 105-8461, Japan</aff>
      <aff id="I3"><label>3</label>Department of Surgery, Jikei University Kashiwa Hospital, 163-1, Kashiwashita, Chiba Prefecture, Kashiwa City 277-8567, Japan</aff>
      <pub-date pub-type="collection">
        <year>2012</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>29</day>
        <month>6</month>
        <year>2012</year>
      </pub-date>
      <volume>10</volume>
      <fpage>129</fpage>
      <lpage>129</lpage>
      <history>
        <date date-type="received">
          <day>4</day>
          <month>12</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>2</day>
          <month>6</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9;2012 Toyama et al.; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2012</copyright-year>
        <copyright-holder>Toyama et al.; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.wjso.com/content/10/1/129"/>
      <abstract>
        <p>A 31-year-old man with sigmoid colon cancer with concomitant simultaneous multiple liver metastases had received FOLFIRI (leucovorin, fluorouracil and irinotecan) and FOLFOX6 (leucovorin, fluorouracil and oxaliplatin) after an ordinary sigmoidectomy. However, his serum carcinoembryonic antigen (CEA) level increased rapidly during the fifteen months after the operation while he was on FOLFOX6. Abdominal computed tomography revealed expanding multiple liver tumors. As the third line chemotherapy, a combination therapy of cetuximab with irinotecan was given, which markedly reduced his levels of serum CEA, and the size and number of liver tumors. He underwent lateral segmentectomy of the liver and microwave coagulation of the liver metastases in the remnant liver. Thereafter, a good quality of life with tumor dormancy was obtained for 6&#x2009;months. However, his serum CEA started to rise again in the absence of liver tumors. Therefore, FOLFOX6 with bevacizumab was chosen as the fourth line chemotherapy, and the serum CEA was reduced with tumor dormancy. A good quality of life was obtained again at 3&#x2009;years after the first surgery. This report indicates the effectiveness of sandwiched liver surgery with the molecular targeting drugs cetuximab and bevacizumab on multiple liver metastases of colon cancer, and suggests the possibility of a regimen consisting of bevacizumab following cetuximab.</p>
      </abstract>
      <kwd-group>
        <kwd>Bevacizumab</kwd>
        <kwd>Cetuximab</kwd>
        <kwd>Colon cancer liver metastases</kwd>
        <kwd>Molecular targeting drug</kwd>
        <kwd>Sandwiched liver surgery</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Recently, various molecular targeting drugs have appeared through developing biotechnology [<xref ref-type="bibr" rid="B1">1</xref>]. Cetuximab, a new molecular drug, has a notable ability as an anti-epidermal growth factor receptor (EGFR) monoclonal antibody [<xref ref-type="bibr" rid="B2">2</xref>]. A randomized European study suggested that cetuximab was effective in patients with irinotecan-refractory metastatic colorectal cancer [<xref ref-type="bibr" rid="B3">3</xref>]. A <italic>KRAS</italic> mutation is an important predictive factor for resistance to cetuximab chemotherapy in patients with metastatic colorectal cancer [<xref ref-type="bibr" rid="B4">4</xref>]. Moreover, it has been reported that the combination of cetuximab and chemotherapy improves the resectability of colorectal cancer liver metastases (CCLM) [<xref ref-type="bibr" rid="B5">5</xref>]. Bevacizumab, an anti-vascular endothelial growth factor receptor (VEGFR) monoclonal antibody, is also an important drug among these new agents [<xref ref-type="bibr" rid="B6">6</xref>]. An open-label study, NO16966, reported the non-inferiority of XELOX (capecitabine and oxaliplatin) to FOLFOX4 (leucovorin (LV), fluorouracil and oxaliplatin) for the first line treatment of metastatic colorectal cancer; however, the additive effect of bevacizumab to the two chemotherapies was not ultimately observed [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B9">9</xref>]. However, the addition of bevacizumab to FOLFOX4 was effective in metastatic colorectal cancer, including in patients with CCLM after first line chemotherapy with FOLFIRI (LV, fluorouracil and irinotecan) [<xref ref-type="bibr" rid="B10">10</xref>]. Furthermore, some reports have indicated that bevacizumab is effective in advanced colorectal cancer refractory to irinotecan, oxaliplatin or cetuximab [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B14">14</xref>]. We herein report a young male patient with CCLM who was treated successfully by a timely sandwiched liver surgery with the molecular targeting drugs, cetuximab and bevacizumab after treatment with FOLFIRI and FOLFOX regimens.</p>
    </sec>
    <sec>
      <title>Case presentation</title>
      <p>A 31-year-old man complained of melena and underwent a colonoscopy that identified a two-thirds circumferential type 2 tumor, an advanced sigmoid cancer. Abdominal computed tomography (CT) showed numerous CCLM. The patient underwent a sigmoidectomy with standard lymph node dissection in our department and histopathological findings revealed a moderately differentiated adenocarcinoma.</p>
      <p>The patient underwent conventional neoadjuvant chemotherapy, first with FOLFIRI (5-fluorocil (FU) 400&#x2009;mg/m<sup>2</sup> bolus injection; LV 400&#x2009;mg/m<sup>2</sup>/2 hours; 5FU 2,400&#x2009;to&#x2009;3,000&#x2009;mg/m<sup>2</sup>/46 hours continuous infusion with irinotecan 180&#x2009;mg/m<sup>2</sup>/1.5 hours, every 2&#x2009;weeks for twenty courses). He was then commenced on FOLFOX6 (Day 1: 5FU 400&#x2009;mg/m<sup>2</sup> bolus injection; LV 200&#x2009;mg/m<sup>2</sup>/2 hours; 5FU 600&#x2009;mg/m<sup>2</sup>/22 hours continuous infusion with oxaliplatin (L-OHP) 85&#x2009;mg/m<sup>2</sup>/2 hours; Day 2: same menu without L-OHP, every 2&#x2009;weeks for eight courses) because abdominal enhanced CT demonstrated enlargement of the CCLM according to Response Evaluation Criteria in Solid Tumors (RECIST) (Figure <xref ref-type="fig" rid="F1">1</xref>). However, in spite of the intensive neoadjuvant chemotherapies, his serum carcinoembryonic antigen (CEA) level gradually increased during the fifteen months following the first operation (Figure <xref ref-type="fig" rid="F2">2</xref>). Since the cancer cells were found to have wild type <italic>KRAS</italic>, a combination therapy of cetuximab with irinotecan was chosen as the third line chemotherapy, considering the possibility of liver surgery for the CCLM. The patient received weekly cetuximab (400&#x2009;mg/m<sup>2</sup> initial dose and 250&#x2009;mg/m<sup>2</sup> per week thereafter) and bi-weekly irinotecan (150&#x2009;mg/m<sup>2</sup>). One course of the combination therapy was defined as 7&#x2009;weeks (six administrations of cetuximab and three administrations of irinotecan, followed by one week&#x2019;s rest). Although the patient initially suffered from facial eczema due to the cetuximab (Figure <xref ref-type="fig" rid="F3">3</xref>), follow-up abdominal enhanced CT demonstrated a marked reduction in the size and number of CCLM (Figure <xref ref-type="fig" rid="F4">4</xref>), and the serum CEA decreased significantly (Figure <xref ref-type="fig" rid="F2">2</xref>).</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Computed tomography demonstrated expanding multiple liver metastases of the sigmoid colon cancer after FOLFIRI and FOLFOX6 therapy.</p>
        </caption>
        <graphic xlink:href="1477-7819-10-129-1"/>
      </fig>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Changes in the serum carcinoembryonic antigen levels of the patient with colon liver metastases after sigmoidectomy.</p>
        </caption>
        <graphic xlink:href="1477-7819-10-129-2"/>
      </fig>
      <fig id="F3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Face eczema appeared as a principal side effect of cetuximab.</p>
        </caption>
        <graphic xlink:href="1477-7819-10-129-3"/>
      </fig>
      <fig id="F4" position="float">
        <label>Figure 4</label>
        <caption>
          <p><bold>Reduction of tumor volume in the liver after the cetuximab and irinotecan treatment.</bold> (<bold>a</bold>) Computed tomography before and (<bold>b</bold>) after the combination treatment with cetuximab and irinotecan.</p>
        </caption>
        <graphic xlink:href="1477-7819-10-129-4"/>
      </fig>
      <p>To obtain further tumor reduction, the patient underwent lateral segmentectomy of the liver (Figure <xref ref-type="fig" rid="F5">5</xref>a) and microwave coagulation for multiple CCLM in the remnant liver. At the second-look operation in this case, obvious hepatotoxicities as such as steatohepatitis and blue liver phenomenon were observed macroscopically. Histology of the operative specimen showed a poorly differentiated metastatic adenocarcinoma derived from colon cancer (Figure <xref ref-type="fig" rid="F5">5</xref>b). As shown in Figure <xref ref-type="fig" rid="F6">6</xref>, postoperative findings by abdominal enhanced CT displayed no variable lesions in the remnant liver.</p>
      <fig id="F5" position="float">
        <label>Figure 5</label>
        <caption>
          <p><bold>Surgical specimen and pathological findings of the second operation.</bold> (<bold>a</bold>) The arrow indicated the cut face side of extirpated lateral segment of the liver. (<bold>b</bold>) Hemotoxylin and eosin staining (&#xD7; 40) showing a moderately differentiated adenocarcinoma.</p>
        </caption>
        <graphic xlink:href="1477-7819-10-129-5"/>
      </fig>
      <fig id="F6" position="float">
        <label>Figure 6</label>
        <caption>
          <p>Computed tomography showed multiple low-density areas in the remnant liver following microwave coagulation.</p>
        </caption>
        <graphic xlink:href="1477-7819-10-129-6"/>
      </fig>
      <p>The patient obtained good quality of life (QOL) with tumor dormancy by addition of the third line chemotherapy during the 6&#x2009;months after the second operation. However, his serum CEA level gradually re-increased even though the third line chemotherapy with the combination of cetuximab and irinotecan was performed (Figure <xref ref-type="fig" rid="F2">2</xref>). Accordingly, a combination of FOLFOX6 with bevacizumab was chosen as the fourth line chemotherapy. His serum CEA level again decreased significantly without any new lesions in the remnant liver. The patient has kept a good QOL with tumor dormancy as of 3&#x2009;years after the first operation.</p>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>Cetuximab, a new molecular drug with an extracellular action site, is expected to remarkably suppress tumor cell mitosis as an anti-EGFR monoclonal antibody [<xref ref-type="bibr" rid="B2">2</xref>]. Additionally, it is known that bevacizumab, a new monoclonal antibody against VEGFR, also inhibits tumor cell proliferation significantly by acting on extracellular receptor sites [<xref ref-type="bibr" rid="B6">6</xref>]. A European randomized trial suggested that cetuximab with or without irinotecan was effective in patients with irinotecan-refractory CCLM [<xref ref-type="bibr" rid="B3">3</xref>]. Thereafter, cetuximab combined with chemotherapies has led to a better prognosis, especially in <italic>KRAS</italic> wild type patients with CCLM [<xref ref-type="bibr" rid="B4">4</xref>]. This was supported by the National Cancer Institute of Canada Clinical Trials Group and Australasian Gastro-Intestinal Trials Group CO.17 trial, which demonstrated that cetuximab offers good QOL and survival benefits for pretreated patients with advanced, wild-type <italic>KRAS</italic> colorectal cancer [<xref ref-type="bibr" rid="B15">15</xref>]. A European Organisation for Research and Treatment of Cancer trial demonstrated that perioperative FOLFOX4 chemotherapy with surgery had advantages over surgery alone [<xref ref-type="bibr" rid="B16">16</xref>]. Thus, to obtain prolonged survival of patients with CCLM, reduction surgery may be effective. Adam <italic>et al</italic>. reported that cetuximab rescued some patients with CCLM by increasing the resectability of those tumors [<xref ref-type="bibr" rid="B5">5</xref>]. The CELIM study by European groups suggested that neoadjuvant chemotherapy with cetuximab yielded high response rates and significantly increased resectability when compared with historical controls [<xref ref-type="bibr" rid="B17">17</xref>]. A European Prospective Investigation into Cancer and Nutrition study indicated that cetuximab with irinotecan improved the QOL in patients with CCLM who failed to exhibit a good response with fluoropyrimidine and oxaliplatin therapy [<xref ref-type="bibr" rid="B18">18</xref>]. Based on these previous studies, we chose the combination therapy of cetuximab with irinotecan as the third line chemotherapy for our patient with the wild type <italic>KRAS</italic> gene. Consequently, the patient could undergo liver surgery and obtain a good QOL with a significant reduction in his serum CEA level over the next 6&#x2009;months.</p>
      <p>Some chemotherapeutic agents have been reported to elicit hepatotoxicities, for example, irinotecan associated with steatohepatitis [<xref ref-type="bibr" rid="B19">19</xref>]. Oxaliplatin has also induced toxic liver injury, which manifests as sinusoidal dilatation or sinusoidal obstruction syndrome, namely blue liver, and nodular regenerative hyperplasia [<xref ref-type="bibr" rid="B20">20</xref>]. However, Pessaux <italic>et al</italic>. have suggested that popular chemotherapy with cetuximab or bevacizumab is not associated with definitive hepatotoxicities [<xref ref-type="bibr" rid="B21">21</xref>-<xref ref-type="bibr" rid="B23">23</xref>]. A recent study indicated that bevacizumab suppresses oxaliplatin-induced liver damage [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>]. Although our patient&#x2019;s liver demonstrated an abnormal gross appearance, there was no major impediment to performing the liver surgery safely.</p>
      <p>Bevacizumab usually has been administrated with FOLFIRI or FOLFOX as first line chemotherapy in patients with CCLM and a poor prognosis, in the hope of obtaining its additive effect [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B9">9</xref>]. However, some reports have shown usefulness of bevacizumab-containing therapy for advanced colorectal cancer patients after failure of irinotecan, oxaliplatin and cetuximab [<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B13">13</xref>]. Results from these reports led us to choose a combination of FOLFOX6 plus bevacizumab as the fourth line chemotherapy.</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusion</title>
      <p>We here describe the successful management of a young adult patient with CCLM with a liver surgery sandwiched between treatment with cetuximab and bevacizumab, suggesting the possibility of bevacizumab administration after cetuximab as a unique and effective therapeutic modality.</p>
    </sec>
    <sec>
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p>
    </sec>
    <sec>
      <title>Abbreviations</title>
      <p>CCLM: colon cancer liver metastases; EGFR: epidermal growth factor receptor; FOLFIRI: leucovorin fluorouracil and irinotecan; FOLFOX: leucovorin fluorouracil and oxaliplatin; LV: Leucovorin; QOL: quality of life; RECIST: Response Evaluation Criteria in Solid Tumors; VGEFR: vascular endothelial growth factor receptor; XELOX: capecitabine and oxaliplatin.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors&#x2019; contributions</title>
      <p>YT and TU performed operation. YT, TU, KW and HK contributed to the conception of chemotherapies, including molecular targeting drugs. All authors analyzed and interpreted the patient data regarding its oncological features, and have been involved in drafting the manuscript. KY had given final approval of the version to be published. All authors read and approved the final manuscript.</p>
    </sec>
    <sec>
      <title>Authors&#x2019; information</title>
      <p>The first author, Yoichi Toyama is specialized in hepatobiliary pancreatic surgery, laparoscopic hepatectomy and pancreatectomy in particular. The second author, Takuro Ushigome, is an expert in colorectal surgery and chemotherapy.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Braun</surname>
            <given-names>AH</given-names>
          </name>
          <name>
            <surname>Achterrath</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Wilke</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Vanhoefer</surname>
            <given-names>U</given-names>
          </name>
          <name>
            <surname>Harstrick</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Preusser</surname>
            <given-names>P</given-names>
          </name>
          <article-title>New systemic frontline treatment for metastatic colorectal carcinoma</article-title>
          <source>Cancer</source>
          <year>2004</year>
          <volume>15</volume>
          <fpage>1558</fpage>
          <lpage>1578</lpage>
          <pub-id pub-id-type="pmid">15073842</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Raymond</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Faivre</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Armand</surname>
            <given-names>JP</given-names>
          </name>
          <article-title>Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy</article-title>
          <source>Drugs</source>
          <year>2000</year>
          <volume>60</volume>
          <fpage>15</fpage>
          <lpage>23</lpage>
          <pub-id pub-id-type="doi">10.2165/00003495-200060001-00002</pub-id>
          <pub-id pub-id-type="pmid">11129168</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Cunningham</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Humblet</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Siena</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Khayat</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Bleiberg</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Santoro</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Bets</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Mueser</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Harstrick</surname>
            <given-names>A</given-names>
          </name>
          <article-title>Cetuximab monotherapy and cetuximab plus irinotecan-refractory metastatic colorectal cancer</article-title>
          <source>N Engl J Med</source>
          <year>2004</year>
          <volume>45</volume>
          <fpage>337</fpage>
          <lpage>345</lpage>
          <pub-id pub-id-type="pmid">15269313</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Li&#xE8;vre</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Bachet</surname>
            <given-names>JB</given-names>
          </name>
          <name>
            <surname>Le Corre</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Boige</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Landi</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Emile</surname>
            <given-names>JF</given-names>
          </name>
          <name>
            <surname>C&#xF4;t&#xE9;</surname>
            <given-names>JF</given-names>
          </name>
          <name>
            <surname>Tomasic</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Penna</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Ducreux</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Rougier</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Penault-Llorca</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Laurent-Puig</surname>
            <given-names>P</given-names>
          </name>
          <article-title>Kras mutation status is predictive of response to cetuximab therapy in colorectal cancer</article-title>
          <source>Cancer Res</source>
          <year>2006</year>
          <volume>66</volume>
          <fpage>3992</fpage>
          <lpage>3995</lpage>
          <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-0191</pub-id>
          <pub-id pub-id-type="pmid">16618717</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Adam</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Aloia</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Levi</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Wicherts</surname>
            <given-names>DA</given-names>
          </name>
          <name>
            <surname>de Haas</surname>
            <given-names>RJ</given-names>
          </name>
          <name>
            <surname>Paule</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Bralet</surname>
            <given-names>MP</given-names>
          </name>
          <name>
            <surname>Bouchahda</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Machover</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Ducreux</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Castagne</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Azoulay</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Castaing</surname>
            <given-names>D</given-names>
          </name>
          <article-title>Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy</article-title>
          <source>J Clin Oncol</source>
          <year>2007</year>
          <volume>25</volume>
          <fpage>4593</fpage>
          <lpage>4602</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2007.10.8126</pub-id>
          <pub-id pub-id-type="pmid">17925554</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Fernando</surname>
            <given-names>NH</given-names>
          </name>
          <name>
            <surname>Hurwitz</surname>
            <given-names>HI</given-names>
          </name>
          <article-title>Targeted therapy of colorectal cancer: clinical experience with bevacizumab</article-title>
          <source>Oncologist</source>
          <year>2004</year>
          <volume>9</volume>
          <fpage>11</fpage>
          <lpage>18</lpage>
          <pub-id pub-id-type="doi">10.1634/theoncologist.9-suppl_1-11</pub-id>
          <pub-id pub-id-type="pmid">15178811</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Tyagi</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Grothey</surname>
            <given-names>A</given-names>
          </name>
          <article-title>Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial</article-title>
          <source>Clin Colorectal Cancer</source>
          <year>2006</year>
          <volume>6</volume>
          <fpage>261</fpage>
          <lpage>264</lpage>
          <pub-id pub-id-type="doi">10.3816/CCC.2006.n.044</pub-id>
          <pub-id pub-id-type="pmid">17241510</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Whyte</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Pandor</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Stevenson</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Rees</surname>
            <given-names>A</given-names>
          </name>
          <article-title>Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer</article-title>
          <source>Health Technol Assess</source>
          <year>2010</year>
          <volume>14</volume>
          <fpage>47</fpage>
          <lpage>53</lpage>
          <pub-id pub-id-type="pmid">21047491</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Cassidy</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Clarke</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Diaz-Rubio</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Scheithauer</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Figer</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Wong</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Koski</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Rittweger</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Gilberg</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Saltz</surname>
            <given-names>L</given-names>
          </name>
          <article-title>XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results</article-title>
          <source>Br J Cancer</source>
          <year>2011</year>
          <volume>105</volume>
          <fpage>58</fpage>
          <lpage>64</lpage>
          <pub-id pub-id-type="doi">10.1038/bjc.2011.201</pub-id>
          <pub-id pub-id-type="pmid">21673685</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Giantonio</surname>
            <given-names>BJ</given-names>
          </name>
          <name>
            <surname>Catalano</surname>
            <given-names>PJ</given-names>
          </name>
          <name>
            <surname>Meropol</surname>
            <given-names>NJ</given-names>
          </name>
          <name>
            <surname>O'Dwyer</surname>
            <given-names>PJ</given-names>
          </name>
          <name>
            <surname>Mitchell</surname>
            <given-names>EP</given-names>
          </name>
          <name>
            <surname>Alberts</surname>
            <given-names>SR</given-names>
          </name>
          <name>
            <surname>Schwartz</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Benson</surname>
            <given-names>AB</given-names>
          </name>
          <collab>Eastern Cooperative Oncology Group Study E3200</collab>
          <article-title>Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200</article-title>
          <source>J Clin Oncol</source>
          <year>2007</year>
          <volume>25</volume>
          <fpage>1539</fpage>
          <lpage>1544</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2006.09.6305</pub-id>
          <pub-id pub-id-type="pmid">17442997</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Emmanouilides</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Pegram</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Robinson</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Hecht</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Kabbinavar</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Isacoff</surname>
            <given-names>W</given-names>
          </name>
          <article-title>Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer</article-title>
          <source>Tech Coloproctol</source>
          <year>2004</year>
          <volume>8</volume>
          <fpage>S50</fpage>
          <lpage>S52</lpage>
          <pub-id pub-id-type="doi">10.1007/s10151-004-0110-4</pub-id>
          <pub-id pub-id-type="pmid">15655642</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Shitara</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Munakata</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Muto</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Sakata</surname>
            <given-names>Y</given-names>
          </name>
          <article-title>Metastatic rectal cancer responding to third-line therapy employing bevacizumab after failure of oxaliplatin and irinotecan: case report</article-title>
          <source>Jpn J Clin Oncol</source>
          <year>2008</year>
          <volume>38</volume>
          <fpage>493</fpage>
          <lpage>496</lpage>
          <pub-id pub-id-type="doi">10.1093/jjco/hyn046</pub-id>
          <pub-id pub-id-type="pmid">18567598</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Gaulin</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Kotb</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Turcotte</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Sawan</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Schmutz</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Beauregard</surname>
            <given-names>P</given-names>
          </name>
          <article-title>Efficacy of third-line therapy using bevacizumab in a patient with metastatic colorectal cancer</article-title>
          <source>Curr Oncol</source>
          <year>2009</year>
          <volume>16</volume>
          <fpage>84</fpage>
          <lpage>86</lpage>
          <pub-id pub-id-type="pmid">19862366</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Li&#xE8;vre</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Samalin</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Mitry</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Assenat</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Boyer-Gestin</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Lep&#xE8;re</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Bachet</surname>
            <given-names>JB</given-names>
          </name>
          <name>
            <surname>Portales</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Vaillant</surname>
            <given-names>JN</given-names>
          </name>
          <name>
            <surname>Ychou</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Rougier</surname>
            <given-names>P</given-names>
          </name>
          <article-title>Bevacizumab plus FORFILI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study</article-title>
          <source>BMC Cancer</source>
          <year>2009</year>
          <volume>9</volume>
          <fpage>347</fpage>
          <pub-id pub-id-type="doi">10.1186/1471-2407-9-347</pub-id>
          <pub-id pub-id-type="pmid">19785749</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Au</surname>
            <given-names>HJ</given-names>
          </name>
          <name>
            <surname>Karapetis</surname>
            <given-names>CS</given-names>
          </name>
          <name>
            <surname>O&#x2019;Callaghan</surname>
            <given-names>CJ</given-names>
          </name>
          <name>
            <surname>Tu</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Moore</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Zalcberg</surname>
            <given-names>JR</given-names>
          </name>
          <name>
            <surname>Kennecke</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Shapiro</surname>
            <given-names>JD</given-names>
          </name>
          <name>
            <surname>Koski</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Pavlakis</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Charpentier</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Wyld</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Jefford</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Knight</surname>
            <given-names>GJ</given-names>
          </name>
          <name>
            <surname>Magoski</surname>
            <given-names>NM</given-names>
          </name>
          <name>
            <surname>Brundage</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Jonker</surname>
            <given-names>DJ</given-names>
          </name>
          <article-title>Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial</article-title>
          <source>J Clin Oncol</source>
          <year>2009</year>
          <volume>27</volume>
          <fpage>1822</fpage>
          <lpage>1828</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2008.19.6048</pub-id>
          <pub-id pub-id-type="pmid">19273701</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Nordlinger</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Sorbye</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Glimelius</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Poston</surname>
            <given-names>GJ</given-names>
          </name>
          <name>
            <surname>Schlag</surname>
            <given-names>PM</given-names>
          </name>
          <name>
            <surname>Rougier</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Bechstein</surname>
            <given-names>WO</given-names>
          </name>
          <name>
            <surname>Primrose</surname>
            <given-names>JN</given-names>
          </name>
          <name>
            <surname>Walpole</surname>
            <given-names>ET</given-names>
          </name>
          <name>
            <surname>Finch-Jones</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Jaeck</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Mirza</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Parks</surname>
            <given-names>RW</given-names>
          </name>
          <name>
            <surname>Collette</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Praet</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Bethe</surname>
            <given-names>U</given-names>
          </name>
          <name>
            <surname>van Cutsem</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Scheithauer</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Gruenberger</surname>
            <given-names>T</given-names>
          </name>
          <collab>EORTC Gastro-Intestinal Tract Cancer Group Cancer Research UK Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO) Australasian Gastro-Intestinal Trials Group (AGITG) F&#xE9;d&#xE9;ration Francophone de Canc&#xE9;rologie Digestive (FFCD)</collab>
          <article-title>Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial</article-title>
          <source>Lancet</source>
          <year>2008</year>
          <volume>22</volume>
          <fpage>1007</fpage>
          <lpage>1016</lpage>
          <pub-id pub-id-type="pmid">18358928</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Foiprecht</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Gruenberger</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Bechstein</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Raab</surname>
            <given-names>HR</given-names>
          </name>
          <name>
            <surname>Lordick</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Hartmann</surname>
            <given-names>JT</given-names>
          </name>
          <name>
            <surname>Lang</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Frilling</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Stoehlmacher</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Weitz</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Konopke</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Stroszczynski</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Liersch</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Ockert</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Herrmann</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Goekkurt</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Parisi</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>K&#xF6;hne</surname>
            <given-names>CH</given-names>
          </name>
          <article-title>Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial</article-title>
          <source>Lancet Oncol</source>
          <year>2010</year>
          <volume>11</volume>
          <fpage>38</fpage>
          <lpage>47</lpage>
          <pub-id pub-id-type="doi">10.1016/S1470-2045(09)70330-4</pub-id>
          <pub-id pub-id-type="pmid">19942479</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Sobrero</surname>
            <given-names>AF</given-names>
          </name>
          <name>
            <surname>Maurel</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Fehrenbacher</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Scheithauer</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Abubakr</surname>
            <given-names>YA</given-names>
          </name>
          <name>
            <surname>Lutz</surname>
            <given-names>MP</given-names>
          </name>
          <name>
            <surname>Vega-Villegas</surname>
            <given-names>ME</given-names>
          </name>
          <name>
            <surname>Eng</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Steinhauer</surname>
            <given-names>EU</given-names>
          </name>
          <name>
            <surname>Prausova</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Lenz</surname>
            <given-names>HJ</given-names>
          </name>
          <name>
            <surname>Borg</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Middleton</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Kr&#xF6;ning</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Luppi</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Kisker</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Zubel</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Langer</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Kopit</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Burris</surname>
            <given-names>HA</given-names>
          </name>
          <article-title>EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer</article-title>
          <source>J Clin Oncol</source>
          <year>2008</year>
          <volume>26</volume>
          <fpage>2311</fpage>
          <lpage>2319</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2007.13.1193</pub-id>
          <pub-id pub-id-type="pmid">18390971</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B19">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Khan</surname>
            <given-names>AZ</given-names>
          </name>
          <name>
            <surname>Morris-Stiff</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Makuuchi</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases</article-title>
          <source>J Hepatobiliary Pancreat Surg</source>
          <year>2009</year>
          <volume>16</volume>
          <fpage>137</fpage>
          <lpage>144</lpage>
          <pub-id pub-id-type="doi">10.1007/s00534-008-0016-z</pub-id>
          <pub-id pub-id-type="pmid">19093069</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B20">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Cleary</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Tanabe</surname>
            <given-names>KT</given-names>
          </name>
          <name>
            <surname>Lauwers</surname>
            <given-names>GY</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>AX</given-names>
          </name>
          <article-title>Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver</article-title>
          <source>Oncologist</source>
          <year>2009</year>
          <volume>14</volume>
          <fpage>1095</fpage>
          <lpage>1105</lpage>
          <pub-id pub-id-type="doi">10.1634/theoncologist.2009-0152</pub-id>
          <pub-id pub-id-type="pmid">19880627</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B21">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Pessaux</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Panaro</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Casnedi</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Zeca</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Marzano</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Bachellier</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Jaeck</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Chenard</surname>
            <given-names>MP</given-names>
          </name>
          <article-title>Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case&#x2013;control study</article-title>
          <source>Eur J Surg Oncol</source>
          <year>2010</year>
          <volume>36</volume>
          <fpage>575</fpage>
          <lpage>582</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejso.2010.04.010</pub-id>
          <pub-id pub-id-type="pmid">20452168</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B22">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Pessaux</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Chenard</surname>
            <given-names>MP</given-names>
          </name>
          <name>
            <surname>Bachellier</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Jaeck</surname>
            <given-names>D</given-names>
          </name>
          <article-title>Consequences of chemotherapy on resection of colorectal liver metastases</article-title>
          <source>J Visc Surg</source>
          <year>2010</year>
          <volume>147</volume>
          <fpage>e193</fpage>
          <lpage>e201</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jviscsurg.2010.06.004</pub-id>
          <pub-id pub-id-type="pmid">20655821</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B23">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Pessaux</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Marzano</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Casnedi</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Bachellier</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Jaeck</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Chenard</surname>
            <given-names>MP</given-names>
          </name>
          <article-title>Histological and immediate postoperative outcome after preoperative cetuximab: case-matched control study</article-title>
          <source>World J Surg</source>
          <year>2010</year>
          <volume>34</volume>
          <fpage>2765</fpage>
          <lpage>2772</lpage>
          <pub-id pub-id-type="doi">10.1007/s00268-010-0731-x</pub-id>
          <pub-id pub-id-type="pmid">20652697</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B24">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Rubbia-Brandt</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Lauwers</surname>
            <given-names>GY</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Majno</surname>
            <given-names>PE</given-names>
          </name>
          <name>
            <surname>Tanabe</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>AX</given-names>
          </name>
          <name>
            <surname>Brezault</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Soubrane</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Abdalla</surname>
            <given-names>EK</given-names>
          </name>
          <name>
            <surname>Vauthey</surname>
            <given-names>JN</given-names>
          </name>
          <name>
            <surname>Mentha</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Terris</surname>
            <given-names>B</given-names>
          </name>
          <article-title>Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis</article-title>
          <source>Histopathology</source>
          <year>2010</year>
          <volume>56</volume>
          <fpage>430</fpage>
          <lpage>439</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2559.2010.03511.x</pub-id>
          <pub-id pub-id-type="pmid">20459550</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B25">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Klinger</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Eipeldauer</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Hacker</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Herberger</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Tamandl</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Dorfmeister</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Koelblinger</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Gruenberger</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Gruenberger</surname>
            <given-names>T</given-names>
          </name>
          <article-title>Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases</article-title>
          <source>Eur J Surg Oncol</source>
          <year>2009</year>
          <volume>35</volume>
          <fpage>515</fpage>
          <lpage>520</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejso.2008.12.013</pub-id>
          <pub-id pub-id-type="pmid">19200687</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
